CD56阳性急性髓系白血病患者的免疫表型分析

Immunophenotypic Analysis of Patients with CD56^+ Acute Myeloid Leukemia

目的:探讨CD56阳性初诊急性髓系白血病(AML)的免疫表型特点。方法:采用四色流式细胞术,以四色抗体组合检测342例初治AML患者白血病细胞免疫表型;根据检测结果CD56分成为CD56阳性组和CD56阴性组,结合细胞形态学分析两组患者的免疫表型特点。结果:在342例AML患者中CD56+患者83例,占24.27%,其中M1 10例,M2 45例,M3 5例,M4 6例,M5 17例。通过统计学分析,患者CD56与CD11b的差异显著,有统计学意义(P<0.05),而与HLA-DR、CD34、CD38、CD13、CD33、CD15、CD117、CD14、CD64、CD2、CD7、CD5、CD3、CD4、CD10、CD19、CD20、CD22之间的差异均无统计学意义(P>0.05)。结论:单独CD56+是AML预后差的标记,但同时对伴有其它免疫标记的AML患者预后需作进一步研究。

Objective: To explore the immunophenotype characteristics of newly diagnosed patients with CD56 +acute myeloid leukemia( AML). Methods: Combining with cytomorphology,four-color flow cytometry was used to analyze the immunophenotype of 342 AML patients with CD56 + or CD56-. Results: In 342 AML patients,the CD56 +expression was found in 83 AML patients who accounted for 24. 27% and included 10 cases of M1,45 cases of M2,5cases of M3,6 cases of M6 and 17 cases of M5. The statistical analysis showed that there was statistical difference between CD56 + and CD11 b + patients( P < 0. 05),but there was no statistical difference between CD56 + and HLA-DR,CD34,CD38,CD13,CD33,CD15,CD117,CD14,CD64,CD2,CD7,CD5,CD3,CD4,CD10,CD19,CD20,CD22( P >0. 05). Conclusion: AML with only CD56 positive always has poor prognosis,thus the prognosis of patients with CD56 + AML accompanied by other antigens still needs more research.